Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells

Cell Research

Volumn 18, Issue 3, 2008, Pages 398-411

  Carlson, Lena Maria ^a   Påhlman, Sven ^b   De Geer, Anna ^a   Kogner, Per ^c   Levitskaya, Jelena ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antigenicity; Cytotoxic lymphocytes; Differentiation; MHC; Neuroblastoma

Indexed keywords

GRANZYME; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; TUMOR ANTIGEN;

ARTICLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NATURAL KILLER CELL; NEUROBLASTOMA; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL LINE, TUMOR; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, NATURAL; NEUROBLASTOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 40249098578     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.27     Document Type: Article

References (39)

1. Marchal JA, Rodriguez-Serrano F, Campos J, et al. Differen-tiation: an encouraging approach to anticancer therapy. Ital J Anat Embryol 2006; 111:45-64.
2. Abelev GI, Lazarevich NL. Control of differentiation in progression of epithelial tumors. Adv Cancer Res 2006; 95:61-113.
3. Edsjo A, Holmquist L, Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxiainduced tumor cell dedifferentiation. Semin Cancer Biol 2006.
4. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-193.
5. Vertuani S, De Geer A, Levitsky V, et al. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res 2003; 63:8006-8013.
6. Martin RF, Beckwith JB. Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg 1968; 3:161-164.
7. Hedborg F, Bjelfman C, Sparen P, Sandstedt B, Pahlman S. Biochemical evidence for a mature phenotype in morphologically poorly differentiated neuroblastomas with a favourable outcome. Eur J Cancer 1995; 31A:435-443.
8. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85:377-384.
9. Svendsen CN, ter Borg MG, Armstrong RJ, et al. A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 1998; 85:141-152.
10. Zorick TS, Lemke G. Schwann cell differentiation. Curr Opin Cell Biol 1996;8:870-876.
11. Schodin BA, Tsomides TJ, Kranz DM. Correlation between the number of T cell receptors required for T cell activation and TCR-ligand affinity. Immunity 1996; 5:137-146.
12. Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlman S. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Differ 1995; 6:727-736.
13. Matsushima H, Bogenmann E. Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol Cell Biol 1993; 13:7447-7456.
14. Poluha W, Poluha DK, Ross AH. TrkA neurogenic receptor regulates differentiation of neuroblastoma cells. Oncogene 1995; 10:185-189.
15. Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. Annu Rev Immunol 2001; 19:375-396.
16. Han ZT, Zhu XX, Yang RY, et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 1998; 95:5357-5361.
17. Strair RK, Schaar D, Goodell L, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002; 8:2512-2518.
18. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3(Suppl 1):72-77.
19. Tonini GP, Pistoia V. Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr Pharm Des 2006; 12:2303-2317.
20. Storch A, Paul G, Csete M, et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 2001; 170:317-325.
21. Lavenius E, Parrow V, Nanberg E, Pahlman S. Basic FGF and IGF-I promote differentiation of human SH-SY5Y neuroblastoma cells in culture. Growth Factors 1994; 10:29-39.
22. Barzilay J, Kushtai G, Plaksin D, Feldman M, Eisenbach L. Expression of major histocompatibility class I genes in differentiating leukemic cells is temporally related to activation of c-fos proto-oncogene. Leukemia 1987; 1:198-204.
23. Bernard DJ, Courjal F, Maurizis JC, et al. Effect of epidermal growth factor in HLA class I and class II transcription and protein expression in human breast adenocarcinoma cell lines. Br J Cancer 1992; 66:88-92.
24. la Sala A, Corinti S, Federici M, Saragovi HU, Girolomoni G. Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. J Leukoc Biol 2000; 68:104-110.
25. Leon JA, Gutierrez MC, Jiang H, et al. Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons. Cancer Immunol Immunother 1992; 35:315-324.
26. Bassi V, De Riu S, Feliciello A, et al. Intercellular adhesion molecule-1 is upregulated via the protein kinase C pathway in human thyroid carcinoma cell lines. Thyroid 1998; 8:23-28.
27. Hunakova L, Sedlak J, Klobusicka M, Sulikova M, Chorvath B. Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity. Neoplasma 1995; 42:249-253.
28. Raychaudhuri SK, Raychaudhuri SP, Weltman H, Farber EM. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch Dermatol Res 2001; 293:291-295.
29. Vertuani S, Dubrovska E, Levitsky V, et al. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol Immunother 2007; 56:193-204.
30. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004; 173:3653-3659.
31. Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol 2003; 13:325-336.
32. Gunturi A, Berg RE, Forman J. The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res 2004; 30:29-34.
33. Bamberger AM, Jenatschke S, Schulte HM, Loning T, Bamberger MC. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab 2000; 85:3932-3936.
34. Shido F, Ito T, Nomura S, et al. Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology 2006; 147:1780-1788.
35. Llano M, Lee N, Navarro F, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998; 28:2854-2863.
36. Whitelegg A, Barber LD. The structural basis of T-cell allorecognition. Tissue Antigens 2004; 63:101-108.
37. Obin M, Mesco E, Gong X, et al. Neurite outgrowth in PC12 cells. Distinguishing the roles of ubiquitylation and ubiquitindependent proteolysis. J Biol Chem 1999; 274:11789-11795.
38. Warzynski MJ, Graham DM, Axtell RA, Higgins JV, Hammers YA. Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients. Cytometry 2002; 50:298-304.
39. Torsteinsdottir S, Masucci MG, Ehlin-Henriksson B, et al. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci USA 1986; 83:5620-5624.